Aptamer Tests Face the Validation Challenge
Clinical adoption will require reproducibility, quality control, and evidence of diagnostic utility
Clinical Scorecard: Aptamer Tests Face the Validation Challenge
At a Glance
| Category | Detail |
|---|
| Condition | Aptamer-based diagnostics |
| Key Mechanisms | Aptamers are short, single-stranded DNA or RNA molecules that bind specific targets, functioning as 'chemical antibodies'. |
| Target Population | Patients requiring molecular diagnostics across various diseases. |
| Care Setting | Clinical laboratories and diagnostic testing environments. |
Key Highlights
- Aptamers can recognize proteins, small molecules, ions, viruses, bacteria, and whole cells.
- New methods like microfluidics and AI are enhancing aptamer selection and performance.
- Aptamer-based tests require validation for analytical sensitivity, specificity, and reproducibility.
Guideline-Based Recommendations
Diagnosis
- Confirm aptamer structure, binding strength, specificity, and performance in clinically relevant samples.
Management
- Utilize aptamer-based platforms for applications such as liquid biopsy and biomarker testing.
Monitoring & Follow-up
- Implement multiplex platforms for disease detection and treatment monitoring.
Risks
- Aptamers may change shape or bind nonspecifically in complex samples, affecting performance.
Patient & Prescribing Data
Patients with cancer, infectious diseases, cardiovascular diseases, neurologic disorders, and metabolic conditions.
Aptamers offer advantages like chemical synthesis and thermal stability, but clinical translation is limited.
Clinical Best Practices
- Ensure standardized quality control and validation in representative patient populations.
- Demonstrate that new tests provide useful information beyond existing methods.
Related Resources & Content
